Spangler JB*, Moraga I*, Jude KM, Savvides CS, Garcia KC. A strategy for the selection of monovalent antibodies that span protein dimer interfaces. J Biol Chem. 2019; 294(38):13876-86). PMID 31387945.

 

Leonard EK, Leff MI, Spangler JB. Weaponizing T-cell receptors through molecular engineering. J Biol Chem. 2019; 294(15):5805-6. PMID 30979848.

 

Krohl PJ, Ludwig SD, Spangler JB. Emerging technologies in protein interface engineering for biomedical applications. Curr Opin Biotechnol. 2019; 60:82-8. PMID 30802788.

Silva DA*, Yu S*, Ulge U*, Spangler JB*, Jude KM, Labão- Almeida C, Ali L, Quijano-Rubio A, Ruterbusch M, Leung I, Biary T, Crowley SJ, Marcos E, Walkey CD, Weitzner BD, Pardo-Avila F, Castellanos J, Carter L, Stewart L, Riddell SR, Pepper M, Bernardes GJL, Dougan M, Garcia KC, Baker D. De novo design of potent and selective mimics of IL-2/IL-15. Nature. 2019; 565(7738):186-91. PMID: 30626941.

 

Spangler JB, Trotta E, Tomala J, Peck A, Young TA, Savvides CS, Silveria S, Votavova P, Salafsky J, Pande VS, Kovar M, Bluestone JA, Garcia KC. Engineering a single-agent cytokine/antibody fusion that selectively expands regulatory T cells for autoimmune disease therapy. J Immunol. 2018; 201(7)2094-106. PMCID: 6173196.

Kureshi R, Bahri M, Spangler JB. Reprogramming immune proteins as therapeutics using molecular engineering. Curr Opin Chem Eng. 2018;19:27-34.

Moraga, I*, Spangler JB*, Menoza JL*, Gakovic M, Wehrman TS, Krutzik P, Garcia KC. Synthekines are surrogate cytokine and growth factor agonists that compel signaling through non-natural receptor dimers. eLife. 2017;6:e22882. PMID: 28498099.

Spangler JB, Tomala J, Luca VC, Jude KM, Dong S, Ring AM, Votavova P, Pepper M, Kovar M, Garcia KC. Antibodies to interleukin-2 elicit selective T cell subset potentiation through distinct conformational mechanisms. Immunity. 2015;42(5):815-25. PMCID: 4439582.

 

Mitra S, Ring AM, Amarnath S, Spangler JB, Li P, Ju W, Fischer S, Oh J, Spolski R, Weiskopf K, Kohrt H, Foley JE, Rajagopalan S, Long EO, Fowler DH, Waldmann TA, Garcia KC, Leonard WJ. Interleukin-2 activity can be fine tuned with engineered receptor signaling clamps. Immunity. 2015;42(5):826-38. PMCID: 4560365.

Spangler JB, Moraga I, Mendoza JL, Garcia KC. Insights into cytokine-receptor interactions from cytokine engineering. Annu Rev Immunol. 2015;33:139-67. PMCID: 4445396.

Moraga I, Spangler J, Mendoza JL, Garcia KC. Multifarious determinants of cytokine receptor signaling specificity. Adv Immunol. 2014;121:1-39. PMCID: 4449261.

Spangler JB, Manzari MT, Rosalia EK, Chen TF, Wittrup KD. Triepitopic antibody fusions inhibit cetuximab-resistant BRAF and KRAS mutant tumors via EGFR signal repression. J Mol Biol. 2012;422(4):532-44. PMCID: 4041985.

Spangler JB, Neil JR, Abramovitch S, Yarden Y, White FM, Lauffenburger DA, Wittrup KD. Combination antibody treatment down-regulates epidermal growth factor receptor by inhibiting endosomal recycling. Proc Natl Acad Sci U S A. 2010;107(30):13252-7. PMCID: 2922117.

You M*, Spangler J*, Li E, Han X, Ghosh P, Hristova K. Effect of pathogenic cysteine mutations on FGFR3 transmembrane domain dimerization in detergents and lipid bilayers. Biochemistry. 2007;46(39):11039-46. PMID: 17845056.

Iwamoto T, You M, Li E, Spangler J, Tomich JM, Hristova K. Synthesis and initial characterization of FGFR3 transmembrane domain: consequences of sequence modifications. Biochim Biophys Acta. 2005;1668(2):240-7. PMID: 15737335.

*PubMed

*Google Scholar

© 2019 by Spangler Lab.